Show news: from last 30 days (default), 60 days, 90 days, last visit or all

FDA approves 2mg naloxone nasal spray

29th December 2016

A 2mg naloxone nasal spray (Narcan; Adapt Pharma) has been approved in the USA. It is approved for use in opioid-dependent patients, expected to be at risk for severe opioid withdrawal, in situations where there is a low risk for accidental or intentional opioid exposure by household contacts.

A 4mg naloxone nasal spray (Narcan; Adapt Pharma) has been available since February 2016 (see our news item 26-11-2016).

The US Product Information for both the 2mg and 4mg naloxone nasal spray can be downloaded from here

click here to view